Participants:

Pr. Arne Ljungqvist, Chairman  Attending
Pr. Eduardo De Rose  Attending
Pr. Theodore Friedmann  Attending
Pr. David Gerrard  Attending
Pr. Carlos Hamilton  Attending
Pr. Luis Horta  Attending
Pr. Ichiro Kono  Attending
Dr. Babette Pluim  Attending
Dr. Patrick Schamasch  Attending
Dr. Bjorn Hedman  Apologies
Dr. Jean-Claude Mbanya  Apologies

WADA Staff
Dr Alain Garnier  Attending
Dr Irene Mazzoni  Attending
Dr Olivier Rabin  Attending

1. Welcome
   • Words of welcome by Arne Ljungqvist.

2. Review of agenda
   • The Agenda is approved.

3. Review of 2007 Prohibited List and recommendation to ExCo
   • The 2007 Draft of the Prohibited List prepared by the List Committee is presented by Olivier Rabin.
   • All changes included in the Draft of the 2007 Prohibited List are accepted by the HM&R Committee.
   • In addition to the changes made by the List Committee, one other modification is included by the HM & R Committee as follows:
     - It is clarified in the Specified Substances section that Salbutamol at concentrations greater than 1000 ng/mL is no longer considered a specified substance.
   • Some topics are subjected to more detailed discussions:
     - T/E ratio: the recommendation of increasing the threshold from 4 to 6, as approved by the List Committee, is discussed and supported. It is agreed that an explanation will be given as why the threshold was lowered 2 years ago and why it is now recommended to be reinstated to 6.
     - Beta-2-agonists: as an action point, it will be attempted to find thresholds that distinguish the legitimate medical use from the abuse of beta-2-agonists, similar to what has been done with salbutamol. WADA will contact pharmaceutical companies to request the pharmacokinetic studies done during the clinical trials; these data may help establishing this threshold. In addition, WADA will contact research groups in the field in order to
carry out excretion studies and studies on anabolic properties of different inhaled beta-2-agonists to clarify these points.

- **Prohibited Methods**: it is discussed and confirmed that hyperbaric oxygen chambers and oxygen tanks are banned under the M1 section.

- **Cannabinoids**: WADA has received information that a metabolite of cannabis may be used to distinguish recent from past use of cannabis. As an action point, Dr Marylin Huestis from NIDA will be contacted on this issue.

- **Monitoring Program**: It was proposed by WADA to reconsider the re-introduction of pseudoephedrine as a banned substance with a threshold, based on evidence WADA has received from the Monitoring Program as well as results from anti-doping control tests. This will be discussed by the List Committee for the 2008 List of Prohibited Substances and will give the stakeholders the opportunity to comment.

- **Artificially-induced hypoxic conditions**: the recommendation of the List Committee for not banning artificially-induced hypoxic conditions is re-affirmed. However, it is advised that a letter should be circulated to the stakeholders warning of the possible health consequences of the improper usage of these hypoxic devices.

- The Draft of 2007 Prohibited List is adopted for proposal to WADA Executive Committee (appendix 1).

4. **Review and recommendation for the 2006 research projects**

- Members of the HM&R Committee responsible for organizing the peer review process and WADA staff present a summary of the evaluations received in their field.

- A ranking of projects within each category is made, and 25 projects are selected (see appendix 2).

- For several projects, budgetary revisions are recommended.

- Three projects were considered important but risky. Therefore, pilot projects of one year duration were recommended in these cases, with further evaluation of the outcomes at the end of the granting period.

- Two ongoing projects which requested extensions were approved but at lower budgets and/or time frames as well as on satisfactory 2006 progress reports.

- The Laboratory Committee will be consulted regarding the possibility of funding one project directly related to their activity.

- It is recommended that research groups that have been funded for projects in the Gene and Cellular Technologies of Relevance to Doping should share the results to avoid overlapping and optimize progress. It is agreed that a clause will be included in the contract to this end and WADA is looking into different mechanisms for facilitating such exchange.

5. **Report from TUE Subcommittee**

- Prof. David Gerrard informs that the draft for the Medical Guidelines document for the granting of TUE is finished and being evaluated by WADA Legal Department. It is stressed that these are only Guidelines and it is up to the Federations to follow them.

6. **Report from Laboratory Subcommittee**

- Prof. Horta gives an update on the Laboratory Subcommittee and informs that Mr Alan Squirrell, Secretary General of ILAC, has been appointed as a new committee member.

- Three laboratories are in probationary accreditation stage: Salt Lake City, New Delhi and Jakarta.

- WADA has circulated in July the revised ISL to the laboratories for consideration.

- It is confirmed that testing by WADA accredited laboratories of Dietary supplements as an outsourcing from private companies will not be allowed.

- It is proposed to extend laboratory participation in the Monitoring Program.

- It is stressed that the information on the medication used by the athletes that appear in the Doping Control Forms is important for the laboratories.
7. Other matters
- The Committee is updated on the status of the commercial development of the growth hormone isoform assay kit.
- The antidoping laboratory in Brazil may have delays in receiving the Proficiency Testing samples due to Customs regulations. It is recommended that WADA continues monitoring the situation and, if needed, contacts the Brazilian Government directly to facilitate the access to substances for the antidoping laboratory.

8. Next meeting
- Since the Executive Committee meeting next year is scheduled for September 15th, it is proposed that the HM&R Committee meeting will take place at the beginning of that month. Since those dates are in conflict with some of the Committee members engagements, the HM & R Committee will request the Executive Committee to delay its meeting for September 22nd, so that the HM & R Committee meeting can take place on September 6th-7th 2007.

Appendices
Appendix 1: the 2007 Prohibited List, as published on September 2006.
Appendix 2: table of recommended research projects for 2006.